Your Yourlocation: Home > Patients with moderate to severe bronchial asthma were treated with budesonide formoterol and tiotropium bromide(136310-93-5)

Anticholinergic drugs are able to antagonize the M receptor, the inhibition of parasympathetic activity, relaxation of bronchial smooth muscle, and thus play the effect of bronchial relaxation. Tiotropium bromide(136310-93-5) is a novel anticholinergic drug that rapidly isolates M2 receptors, inhibits sympathetic nerve activity, relaxes bronchial smooth muscle, and tiotropium also blocks acetylcholine release Acetylcholine activates the M receptor - induced inflammatory response and exerts a certain anti - inflammatory effect. Tiotropium diastolic bronchial mechanism of action is different from the general bronchodilator, according to foreign studies have shown that anticholinergic drugs and β

2 receptor agonist combination, can effectively enhance the β2 receptor agonist efficacy. In this study, the ACT score of the study group after treatment was significantly higher than the control group, the cure rate, the total effective rate was significantly higher than the control group, SGRO score was significantly lower than the control group, P <0.05. This suggests that the combination of budesonide, tiotropium bromide(136310-93-5) and budesonide formoterol alone may be effective in improving bronchial asthma symptoms, improving clinical control of bronchial asthma, The quality of life of patients. The FEV1, FEF and PEF of the study group were also significantly higher than those of the control group (P <0.05). This result is consistent with the domestic literature, suggesting that tiotropium bromide and budesonide formoterol can effectively improve lung function in patients with bronchial asthma. The levels of EOS and IgG in the study group were significantly lower than those in the control group (P <0.05). This suggests that tiotropium bromide(136310-93-5) in the treatment of bronchial asthma can not only improve symptoms, dilate the airway, improve lung function, but also has a specific anti-inflammatory effect.

Bronchial asthma is more common in clinical practice, is a chronic inflammatory disease, standard anti-inflammatory treatment helps control asthma attacks, relieve clinical symptoms. According to the asthma treatment guidelines related to treatment, about half of the asthma can be completely controlled, 4/5 or more of asthma can achieve partial control effect.

In short, moderate to severe bronchial asthma patients with budesonide formoterol and tiotropium bromide(136310-93-5) treatment, can better control asthma attacks, relieve clinical symptoms, while enhancing lung function, improve patient quality of life, its clinical application advantages is significant, worthy of promotion.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved